{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:45:04Z","timestamp":1758044704540,"version":"3.44.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100015360","name":"State Key Laboratory of Infectious Disease Prevention and Control","doi-asserted-by":"publisher","award":["2020SKLID102"],"award-info":[{"award-number":["2020SKLID102"]}],"id":[{"id":"10.13039\/501100015360","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U20A20362"],"award-info":[{"award-number":["U20A20362"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00705-025-06372-9","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T16:49:33Z","timestamp":1756140573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Two cross-neutralizing antibodies isolated from a COVID-19 convalescent via single B cell sorting"],"prefix":"10.1007","volume":"170","author":[{"given":"Yuanyuan","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiqin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junwei","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4177-6038","authenticated-orcid":false,"given":"Yiming","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"issue":"3","key":"6372_CR1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","volume":"185","author":"W Dejnirattisai","year":"2022","unstructured":"Dejnirattisai W, Huo J, Zhou D, Zahradnik J, Supasa P, Liu C, Duyvesteyn HME, Ginn HM, Mentzer AJ, Tuekprakhon A et al (2022) SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 185(3):467\u2013484 e415","journal-title":"Cell"},{"issue":"1","key":"6372_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12929-022-00852-9","volume":"29","author":"M Kumari","year":"2022","unstructured":"Kumari M, Lu RM, Li MC, Huang JL, Hsu FF, Ko SH, Ke FY, Su SC, Liang KH, Yuan JP et al (2022) A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. J Biomed Sci 29(1):68","journal-title":"J Biomed Sci"},{"issue":"12","key":"6372_CR3","doi-asserted-by":"publisher","first-page":"113444","DOI":"10.1016\/j.celrep.2023.113444","volume":"42","author":"RJ Parsons","year":"2023","unstructured":"Parsons RJ, Acharya P (2023) Evolution of the SARS-CoV-2 Omicron spike. Cell Rep 42(12):113444","journal-title":"Cell Rep"},{"issue":"6591","key":"6372_CR4","doi-asserted-by":"publisher","first-page":"eabn8897","DOI":"10.1126\/science.abn8897","volume":"376","author":"T Zhou","year":"2022","unstructured":"Zhou T, Wang L, Misasi J, Pegu A, Zhang Y, Harris DR, Olia AS, Talana CA, Yang ES, Chen M et al (2022) Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. Science 376(6591):eabn8897","journal-title":"Science"},{"issue":"1","key":"6372_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12929-023-00955-x","volume":"30","author":"HL Chiang","year":"2023","unstructured":"Chiang HL, Liang KH, Lu RM, Kuo TW, Lin YL, Wu HC (2023) Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2. J Biomed Sci 30(1):59","journal-title":"J Biomed Sci"},{"issue":"7906","key":"6372_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","volume":"604","author":"S Iketani","year":"2022","unstructured":"Iketani S, Liu L, Guo Y, Liu L, Chan JF, Huang Y, Wang M, Luo Y, Yu J, Chu H et al (2022) Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604(7906):553\u2013556","journal-title":"Nature"},{"issue":"7898","key":"6372_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","volume":"602","author":"L Liu","year":"2022","unstructured":"Liu L, Iketani S, Guo Y, Chan JF, Wang M, Liu L, Luo Y, Chu H, Huang Y, Nair MS et al (2022) Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602(7898):676\u2013681","journal-title":"Nature"},{"issue":"1","key":"6372_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.chom.2022.11.012","volume":"31","author":"P Qu","year":"2023","unstructured":"Qu P, Evans JP, Faraone JN, Zheng YM, Carlin C, Anghelina M, Stevens P, Fernandez S, Jones D, Lozanski G et al (2023) Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Cell Host Microbe 31(1):9\u201317 e13","journal-title":"Cell Host Microbe"},{"issue":"5","key":"6372_CR9","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1002\/jmv.27588","volume":"94","author":"Y Araf","year":"2022","unstructured":"Araf Y, Akter F, Tang YD, Fatemi R, Parvez MSA, Zheng C, Hossain MG (2022) Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol 94(5):1825\u20131832","journal-title":"J Med Virol"},{"issue":"4","key":"6372_CR10","doi-asserted-by":"publisher","first-page":"e2358","DOI":"10.1002\/rmv.2358","volume":"32","author":"A Lino","year":"2022","unstructured":"Lino A, Cardoso MA, Martins-Lopes P, Goncalves HMR (2022) Omicron - The new SARS-CoV-2 challenge? Rev Med Virol 32(4):e2358","journal-title":"Rev Med Virol"},{"issue":"4","key":"6372_CR11","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/jmv.27524","volume":"94","author":"SK Saxena","year":"2022","unstructured":"Saxena SK, Kumar S, Ansari S, Paweska JT, Maurya VK, Tripathi AK, Abdel-Moneim AS (2022) Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective. J Med Virol 94(4):1738\u20131744","journal-title":"J Med Virol"},{"issue":"5","key":"6372_CR12","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1002\/jmv.27558","volume":"94","author":"S Majumdar","year":"2022","unstructured":"Majumdar S, Sarkar R (2022) Mutational and phylogenetic analyses of the two lineages of the Omicron variant. J Med Virol 94(5):1777\u20131779","journal-title":"J Med Virol"},{"issue":"9","key":"6372_CR13","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/s41591-022-01911-2","volume":"28","author":"H Tegally","year":"2022","unstructured":"Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, Subramoney K, Makatini Z, Moyo S, Amoako DG et al (2022) Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med 28(9):1785\u20131790","journal-title":"Nat Med"},{"issue":"4","key":"6372_CR14","doi-asserted-by":"publisher","first-page":"e28714","DOI":"10.1002\/jmv.28714","volume":"95","author":"F Scarpa","year":"2023","unstructured":"Scarpa F, Giovanetti M, Azzena I, Locci C, Casu M, Fiori PL, Ciccozzi A, Imperia E, Bazzani L, Borsetti A et al (2023) Genome-based survey of the SARS-CoV-2 BF.7 variant from Asia. J Med Virol 95(4):e28714","journal-title":"J Med Virol"},{"issue":"2","key":"6372_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","volume":"186","author":"Q Wang","year":"2023","unstructured":"Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, Bowen AD, Liu M, Wang M, Yu J et al (2023) Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 186(2):279\u2013286 e278","journal-title":"Cell"},{"key":"6372_CR16","unstructured":"Abdolreza E, Fereshteh E, Armin JM, Amir S (2024) EG.5 (Eris) and BA.2.86 (Pirola) two new subvariants of SARS-CoV-2: a new face of old COVID-19. Infection"},{"key":"6372_CR17","doi-asserted-by":"publisher","first-page":"100794","DOI":"10.1016\/j.drup.2021.100794","volume":"59","author":"S Drozdzal","year":"2021","unstructured":"Drozdzal S, Rosik J, Lechowicz K, Machaj F, Szostak B, Przybycinski J, Lorzadeh S, Kotfis K, Ghavami S, Los MJ (2021) An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment. Drug Resist Updat 59:100794","journal-title":"Drug Resist Updat"},{"issue":"2","key":"6372_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41579-022-00809-7","volume":"21","author":"M Cox","year":"2023","unstructured":"Cox M, Peacock TP, Harvey WT, Hughes J, Wright DW, Consortium C-GU, Willett BJ, Thomson E, Gupta RK, Peacock SJ et al (2023) SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat Rev Microbiol 21(2):112\u2013124","journal-title":"Nat Rev Microbiol"},{"key":"6372_CR19","doi-asserted-by":"crossref","unstructured":"Miyashita N, Nakamori Y, Ogata M, Fukuda N, Yamura A, Ishiura Y, Ito T (2023) Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections. Viruses 15(6)","DOI":"10.3390\/v15061300"},{"issue":"11","key":"6372_CR20","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1016\/S1473-3099(22)00311-5","volume":"22","author":"D Focosi","year":"2022","unstructured":"Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M (2022) Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect Dis 22(11):e311\u2013e326","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"6372_CR21","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s10787-023-01253-6","volume":"31","author":"M Sabbatucci","year":"2023","unstructured":"Sabbatucci M, Vitiello A, Clemente S, Zovi A, Boccellino M, Ferrara F, Cimmino C, Langella R, Ponzo A, Stefanelli P et al (2023) Omicron variant evolution on vaccines and monoclonal antibodies. Inflammopharmacology 31(4):1779\u20131788","journal-title":"Inflammopharmacology"},{"key":"6372_CR22","doi-asserted-by":"publisher","first-page":"1160283","DOI":"10.3389\/fimmu.2023.1160283","volume":"14","author":"Z Wang","year":"2023","unstructured":"Wang Z, Li D, Chen Y, Sun Y, Jin C, Hu C, Feng Y, Su J, Ren L, Hao Y et al (2023) Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents. Front Immunol 14:1160283","journal-title":"Front Immunol"},{"issue":"7923","key":"6372_CR23","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","volume":"608","author":"Y Cao","year":"2022","unstructured":"Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, Du S, Wang J, Li Q, Chen X et al (2022) BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608(7923):593\u2013602","journal-title":"Nature"},{"issue":"7898","key":"6372_CR24","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R et al (2022) Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602(7898):657\u2013663","journal-title":"Nature"},{"issue":"1","key":"6372_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12967-025-06162-6","volume":"23","author":"D Li","year":"2025","unstructured":"Li D, Hu C, Su J, Du S, Zhang Y, Ni W, Ren L, Hao Y, Feng Y, Jin C et al (2025) Function and structure of broadly neutralizing antibodies against SARS-CoV-2 Omicron variants isolated from prototype strain infected convalescents. J Transl Med 23(1):212","journal-title":"J Transl Med"},{"issue":"4","key":"6372_CR26","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/pathogens13040272","volume":"13","author":"Y Hu","year":"2024","unstructured":"Hu Y, Hu C, Wang S, Ren L, Hao Y, Wang Z, Liu Y, Su J, Zhu B, Li D et al (2024) Identification of an IGHV3-53-Encoded RBD-Targeting Cross-Neutralizing Antibody from an Early COVID-19 Convalescent. Pathogens 13(4):272","journal-title":"Pathogens"},{"issue":"4","key":"6372_CR27","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.immuni.2016.03.006","volume":"44","author":"L Kong","year":"2016","unstructured":"Kong L, Ju B, Chen Y, He L, Ren L, Liu J, Hong K, Su B, Wang Z, Ozorowski G et al (2016) Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor. Immunity 44(4):939\u2013950","journal-title":"Immunity"},{"key":"6372_CR28","doi-asserted-by":"crossref","unstructured":"Kumar S, Ju B, Shapero B, Lin X, Ren L, Zhang L, Li D, Zhou Z, Feng Y, Sou C et al (2020) A V(H)1\u201369 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite. Sci Adv 6(38)","DOI":"10.1126\/sciadv.abb1328"},{"issue":"1\u20132","key":"6372_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jim.2007.09.017","volume":"329","author":"T Tiller","year":"2008","unstructured":"Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H (2008) Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 329(1\u20132):112\u2013124","journal-title":"J Immunol Methods"},{"key":"6372_CR30","doi-asserted-by":"publisher","first-page":"198470","DOI":"10.1016\/j.virusres.2021.198470","volume":"302","author":"Y Hu","year":"2021","unstructured":"Hu Y, Li D, Fu H, Hao Y, Ren L, Wang S, Hu X, Shao Y, Hong K, Wang Z (2021) Identification of a CD4-binding site-directed antibody with ADCC activity from a chronic HIV-1B'-infected Chinese donor. Virus Res 302:198470","journal-title":"Virus Res"},{"issue":"1","key":"6372_CR31","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","volume":"9","author":"J Nie","year":"2020","unstructured":"Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, Zhang L, Nie L, Qin H, Wang M et al (2020) Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect 9(1):680\u2013686","journal-title":"Emerg Microbes Infect"},{"key":"6372_CR32","doi-asserted-by":"publisher","first-page":"978440","DOI":"10.3389\/fcimb.2022.978440","volume":"12","author":"C Hu","year":"2022","unstructured":"Hu C, Wang Z, Ren L, Hao Y, Zhu M, Jiang H, Wang S, Li D, Shao Y (2022) Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination. Front Cell Infect Microbiol 12:978440","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"6372_CR33","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1038\/s41467-023-37926-7","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wang Z, Zhuang X, Zhang S, Chen Z, Zou Y, Sheng J, Li T, Tai W, Yu J et al (2023) Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants. Nat Commun 14(1):2179","journal-title":"Nat Commun"},{"issue":"1","key":"6372_CR34","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1038\/s41467-021-24123-7","volume":"12","author":"TJC Tan","year":"2021","unstructured":"Tan TJC, Yuan M, Kuzelka K, Padron GC, Beal JR, Chen X, Wang Y, Rivera-Cardona J, Zhu X, Stadtmueller BM et al (2021) Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain. Nat Commun 12(1):3815","journal-title":"Nat Commun"},{"issue":"4","key":"6372_CR35","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.cell.2020.06.025","volume":"182","author":"CO Barnes","year":"2020","unstructured":"Barnes CO, West AP Jr., Huey-Tubman KE, Hoffmann MAG, Sharaf NG, Hoffman PR, Koranda N, Gristick HB, Gaebler C, Muecksch F et al (2020) Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell 182(4):828\u2013842e816","journal-title":"Cell"},{"key":"6372_CR36","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.bbrc.2020.10.012","volume":"538","author":"M Yuan","year":"2021","unstructured":"Yuan M, Liu H, Wu NC, Wilson IA (2021) Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. Biochem Biophys Res Commun 538:192\u2013203","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"6372_CR37","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.cell.2020.09.035","volume":"183","author":"S Du","year":"2020","unstructured":"Du S, Cao Y, Zhu Q, Yu P, Qi F, Wang G, Du X, Bao L, Deng W, Zhu H et al (2020) Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. Cell 183(4):1013\u20131023e1013","journal-title":"Cell"},{"issue":"10","key":"6372_CR38","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1016\/j.cell.2021.03.027","volume":"184","author":"SA Clark","year":"2021","unstructured":"Clark SA, Clark LE, Pan J, Coscia A, McKay LGA, Shankar S, Johnson RI, Brusic V, Choudhary MC, Regan J et al (2021) SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms. Cell 184(10):2605\u20132617 e2618","journal-title":"Cell"},{"issue":"6556","key":"6372_CR39","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.abh1139","volume":"373","author":"M Yuan","year":"2021","unstructured":"Yuan M, Huang D, Lee CD, Wu NC, Jackson AM, Zhu X, Liu H, Peng L, van Gils MJ, Sanders RW et al (2021) Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science 373(6556):818\u2013823","journal-title":"Science"},{"issue":"6507","key":"6372_CR40","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1126\/science.abd2321","volume":"369","author":"M Yuan","year":"2020","unstructured":"Yuan M, Liu H, Wu NC, Lee CD, Zhu X, Zhao F, Huang D, Yu W, Hua Y, Tien H et al (2020) Structural basis of a shared antibody response to SARS-CoV-2. Science 369(6507):1119\u20131123","journal-title":"Science"},{"issue":"1","key":"6372_CR41","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41392-020-00287-4","volume":"5","author":"F Fagiani","year":"2020","unstructured":"Fagiani F, Catanzaro M, Lanni C (2020) Molecular features of IGHV3-53-encoded antibodies elicited by SARS-CoV-2. Signal Transduct Target Ther 5(1):170","journal-title":"Signal Transduct Target Ther"},{"issue":"6506","key":"6372_CR42","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1126\/science.abc7520","volume":"369","author":"TF Rogers","year":"2020","unstructured":"Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, Limbo O, Smith C, Song G, Woehl J et al (2020) Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 369(6506):956\u2013963","journal-title":"Science"},{"issue":"9","key":"6372_CR43","doi-asserted-by":"publisher","first-page":"109627","DOI":"10.1016\/j.celrep.2021.109627","volume":"36","author":"IM Francino-Urdaniz","year":"2021","unstructured":"Francino-Urdaniz IM, Steiner PJ, Kirby MB, Zhao F, Haas CM, Barman S, Rhodes ER, Leonard AC, Peng L, Sprenger KG et al (2021) One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening. Cell Rep 36(9):109627","journal-title":"Cell Rep"},{"issue":"8","key":"6372_CR44","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.immuni.2022.06.005","volume":"55","author":"M Huang","year":"2022","unstructured":"Huang M, Wu L, Zheng A, Xie Y, He Q, Rong X, Han P, Du P, Han P, Zhang Z et al (2022) Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1\/BA.1.1\/BA.2\/BA.3. Immunity 55(8):1501\u20131514 e1503","journal-title":"Immunity"},{"key":"6372_CR45","doi-asserted-by":"publisher","first-page":"100272","DOI":"10.1016\/j.lansea.2023.100272","volume":"19","author":"ST Selvavinayagam","year":"2023","unstructured":"Selvavinayagam ST, Karishma SJ, Hemashree K, Yong YK, Suvaithenamudhan S, Rajeshkumar M, Aswathy B, Kalaivani V, Priyanka J, Kumaresan A et al (2023) Clinical characteristics and novel mutations of omicron subvariant XBB in Tamil Nadu, India - a cohort study. Lancet Reg Health Southeast Asia 19:100272","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"6","key":"6372_CR46","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1002\/jmv.27643","volume":"94","author":"D Tian","year":"2022","unstructured":"Tian D, Sun Y, Xu H, Ye Q (2022) The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant. J Med Virol 94(6):2376\u20132383","journal-title":"J Med Virol"},{"issue":"4","key":"6372_CR47","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/s41590-023-01449-6","volume":"24","author":"B Ju","year":"2023","unstructured":"Ju B, Zhang Q, Wang Z, Aw ZQ, Chen P, Zhou B, Wang R, Ge X, Lv Q, Cheng L et al (2023) Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants. Nat Immunol 24(4):690\u2013699","journal-title":"Nat Immunol"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-025-06372-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-025-06372-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-025-06372-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T15:02:20Z","timestamp":1757689340000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-025-06372-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6372"],"URL":"https:\/\/doi.org\/10.1007\/s00705-025-06372-9","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"type":"print","value":"0304-8608"},{"type":"electronic","value":"1432-8798"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the First Affiliated Hospital, Zhejiang University School of Medicine (approval no. 2020433). Written informed consent was obtained from donor SW prior to the collection of blood samples and data. The donor is a legal citizen of China.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All authors have read and agreed to the final version of the manuscript, and the authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"199"}}